Exploring beyond numeric weight loss: The metabolic effects of semaglutide
<p dir="ltr">The global burden of overweight and obesity has increased by threefold since the 1970s, which led to increased incidences of cardiovascular disease and <u>type 2 diabetes</u>. This review aimed to explore the metabolic impacts of <u>semaglutide</u>...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513534673551360 |
|---|---|
| author | Sara Sokary (17337724) |
| author2 | Hiba Bawadi (3436379) |
| author2_role | author |
| author_facet | Sara Sokary (17337724) Hiba Bawadi (3436379) |
| author_role | author |
| dc.creator.none.fl_str_mv | Sara Sokary (17337724) Hiba Bawadi (3436379) |
| dc.date.none.fl_str_mv | 2025-04-02T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.clnesp.2025.03.010 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Exploring_beyond_numeric_weight_loss_The_metabolic_effects_of_semaglutide/30405193 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences Body composition Glucagon-like Peptide-1 receptor agonist Glycemic control Hunger and satiety Lipid profile Semaglutide Weight maintenance |
| dc.title.none.fl_str_mv | Exploring beyond numeric weight loss: The metabolic effects of semaglutide |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">The global burden of overweight and obesity has increased by threefold since the 1970s, which led to increased incidences of cardiovascular disease and <u>type 2 diabetes</u>. This review aimed to explore the metabolic impacts of <u>semaglutide</u>, including its effects on hunger and satiety, weight loss maintenance and regain, body composition, lipid profile, and <u>glycemic control</u>. Studies have shown that <u>semaglutide </u>reduced fat mass, particularly <u>visceral fat</u>, while preserving lean muscle mass, as the proportion relative to total body mass decreased by 3.5 % and 2.0 % for total and visceral fat mass, respectively, while it increased by 3.0 % for <u>lean body mass</u>. Also, it enhanced glycemic control, as evidenced by significant reductions in hemoglobin A1C (HbA1c) with the 0.5 mg and 1.0 mg doses. From a baseline range of 8.1–8.7 %, 0.5 mg dose lowered HbA1c by 1.2–1.5 %, while the 1.0 mg dose reduced it by 1.4–1.8 %. Furthermore, semaglutide was the only effective Glucagon Like Peptide-1 Receptor Agonist in reducing Low-Density Lipoprotein and total cholesterol levels, with mean differences of −0.16 mmol/L and −0.48 mmol/L, respectively. Evidence shows that withdrawing semaglutide led to weight regain, while continued treatment resulted in further weight loss. Semaglutide also slowed weight regain and promoted weight loss after failed <u>bariatric surgery.</u> It also significantly reduced ad libitum <u>energy intake</u>, decreased hunger, and increased satiety in multiple trials. Overall, these findings underscore the potential of semaglutide as a comprehensive treatment for obesity and type 2 diabetes.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Nutrition ESPEN<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.clnesp.2025.03.010" target="_blank">https://dx.doi.org/10.1016/j.clnesp.2025.03.010</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_6c4f8abd9cd84340de38c81630844297 |
| identifier_str_mv | 10.1016/j.clnesp.2025.03.010 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/30405193 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Exploring beyond numeric weight loss: The metabolic effects of semaglutideSara Sokary (17337724)Hiba Bawadi (3436379)Biomedical and clinical sciencesCardiovascular medicine and haematologyMedical biochemistry and metabolomicsPharmacology and pharmaceutical sciencesBody compositionGlucagon-like Peptide-1 receptor agonistGlycemic controlHunger and satietyLipid profileSemaglutideWeight maintenance<p dir="ltr">The global burden of overweight and obesity has increased by threefold since the 1970s, which led to increased incidences of cardiovascular disease and <u>type 2 diabetes</u>. This review aimed to explore the metabolic impacts of <u>semaglutide</u>, including its effects on hunger and satiety, weight loss maintenance and regain, body composition, lipid profile, and <u>glycemic control</u>. Studies have shown that <u>semaglutide </u>reduced fat mass, particularly <u>visceral fat</u>, while preserving lean muscle mass, as the proportion relative to total body mass decreased by 3.5 % and 2.0 % for total and visceral fat mass, respectively, while it increased by 3.0 % for <u>lean body mass</u>. Also, it enhanced glycemic control, as evidenced by significant reductions in hemoglobin A1C (HbA1c) with the 0.5 mg and 1.0 mg doses. From a baseline range of 8.1–8.7 %, 0.5 mg dose lowered HbA1c by 1.2–1.5 %, while the 1.0 mg dose reduced it by 1.4–1.8 %. Furthermore, semaglutide was the only effective Glucagon Like Peptide-1 Receptor Agonist in reducing Low-Density Lipoprotein and total cholesterol levels, with mean differences of −0.16 mmol/L and −0.48 mmol/L, respectively. Evidence shows that withdrawing semaglutide led to weight regain, while continued treatment resulted in further weight loss. Semaglutide also slowed weight regain and promoted weight loss after failed <u>bariatric surgery.</u> It also significantly reduced ad libitum <u>energy intake</u>, decreased hunger, and increased satiety in multiple trials. Overall, these findings underscore the potential of semaglutide as a comprehensive treatment for obesity and type 2 diabetes.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical Nutrition ESPEN<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.clnesp.2025.03.010" target="_blank">https://dx.doi.org/10.1016/j.clnesp.2025.03.010</a></p>2025-04-02T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.clnesp.2025.03.010https://figshare.com/articles/journal_contribution/Exploring_beyond_numeric_weight_loss_The_metabolic_effects_of_semaglutide/30405193CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/304051932025-04-02T06:00:00Z |
| spellingShingle | Exploring beyond numeric weight loss: The metabolic effects of semaglutide Sara Sokary (17337724) Biomedical and clinical sciences Cardiovascular medicine and haematology Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences Body composition Glucagon-like Peptide-1 receptor agonist Glycemic control Hunger and satiety Lipid profile Semaglutide Weight maintenance |
| status_str | publishedVersion |
| title | Exploring beyond numeric weight loss: The metabolic effects of semaglutide |
| title_full | Exploring beyond numeric weight loss: The metabolic effects of semaglutide |
| title_fullStr | Exploring beyond numeric weight loss: The metabolic effects of semaglutide |
| title_full_unstemmed | Exploring beyond numeric weight loss: The metabolic effects of semaglutide |
| title_short | Exploring beyond numeric weight loss: The metabolic effects of semaglutide |
| title_sort | Exploring beyond numeric weight loss: The metabolic effects of semaglutide |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences Body composition Glucagon-like Peptide-1 receptor agonist Glycemic control Hunger and satiety Lipid profile Semaglutide Weight maintenance |